KRAS and lung cancer: In pleural effusion-derived cells from lung cancer patients, 8-OHdG coexists with KRAS and TP53 mutations at frequencies of 64.2% and 69.8%, respectively, findings that provide empirical evidence for its synergistic contribution to tumor progression.